摘要
目的:观察信必可都保与孟鲁司特两药联合治疗中重度支气管哮喘(简称哮喘)的效果。方法:将72例中重度哮喘患儿随机分为观察组(n=36)和对照组(n=36),观察组应用信必可都保加用孟鲁司特,对照组应用信必可都保,比较两组患儿治疗前和治疗后3个月第1秒用力呼出量/用力肺活量(FEV1/FVC)、呼气峰流速(PEF)、日间症状评分、夜间症状评分及嗜酸性粒细胞(EOS)计数。结果:观察组治疗后较对照组日间症状评分、夜间症状评分、EOS降低,而FEV1/FVC、PEF增加,差异均有统计学意义(P<0.05)。结论:信必可都保联合孟鲁司特治疗儿童中重度哮喘可明显减轻哮喘症状,疗效优于单用布地奈德福莫特罗粉吸入剂。
Objective To observe the therapeutic effectiveness of symhicort turbuhaler plus montelukast on moderate and severe bron- chial asthma. Method Seventy - two cases were randomly divided into observational group （ n = 36 ） and control group （ n = 36 ） . Observational group was treated with symhicort turbuhalcr and montelukast, whereas control group was treated with symhicort turbuhal- er. FEVI/FVC, PEF, daytime symptom score, nighttime symptom score and EOS were compared between two groups 3 months before and af- ter treatment. Results In comparison with control group, daytime symptom score, nighttime symptom score and EOS were decreased while FEVI/FVC and PEF were increased in observational group after treatment （P 〈0. 05 ）. Conclusion Symbicort turbuhaler in combination with montelukast may obviously alleviate the symptom of moderate and severe bronchial asthma, and the therapeutic effectiveness is better than symbicort turbuhaler.
出处
《吉林医学》
CAS
2013年第25期5116-5117,共2页
Jilin Medical Journal
基金
湖南省卫生厅课题资助项目[项目编号:B2012-048]
关键词
支气管哮喘
信必可都保
孟鲁司特
Bronchial asthma
Symbicort turbuhaler
Montelukast
